Arca
Skip to content
Tools
Tools

APP: Amyloid-beta precursor protein

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis.

  • Drugs that act on it: 13
  • Approved: 3
  • In phases 1 to 3: 10
  • Sponsors: 9

Who Is On It, and How Far Along

Every drug ChEMBL records acting on APP, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody
  • Protein or peptide
  • Other

Approved3

  • Lecanemab
  • Donanemab
  • Aducanumab

Phase 36

  • Gantenerumab
  • Solanezumab
  • Bapineuzumab
  • Crenezumab
  • Tramiprosate
  • Valiltramiprosate

Phase 24

  • Amilomotide
  • GSK933776
  • Ponezumab
  • Vanutide cridificar

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Alzheon Inc.18%
    • Bellus Health Inc. - a GSK company18%

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule215%
    • Antibody862%
    • Protein or peptide215%
    • Other18%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
    LecanemabApprovedEisaiAntibodyInhibitorAmyloid-beta A4 protein inhibitor30Boxed warning
    DonanemabApprovedEli LillyAntibodyDisrupting agentAmyloid-beta A4 protein disrupting agent15—
    AducanumabApprovedBiogenAntibodyBinding agentAmyloid-beta A4 protein binding agent1Boxed warning
    GantenerumabPhase 3RocheAntibodyBinding agentAmyloid-beta A4 protein binding agent1—
    SolanezumabPhase 3Eli LillyAntibodyBinding agentAmyloid-beta A4 protein binding agent1—
    BapineuzumabPhase 3PfizerAntibodyBinding agentAmyloid-beta A4 protein binding agent0—
    CrenezumabPhase 3RocheAntibodyInhibitorAmyloid-beta A4 protein inhibitor0—
    TramiprosatePhase 3Bellus Health Inc. - a GSK companySmall moleculeStabiliserAmyloid-beta A4 protein stabiliser0—
    ValiltramiprosatePhase 3Alzheon Inc.Small moleculeStabiliserAmyloid-beta A4 protein stabiliser0—
    AmilomotidePhase 2Novartis PharmaceuticalsProtein or peptideVaccine antigenAmyloid-beta A4 protein vaccine antigen0—
    GSK933776Phase 2GSKOtherBinding agentAmyloid-beta A4 protein binding agent0—
    PonezumabPhase 2PfizerAntibodyBinding agentAmyloid-beta A4 protein binding agent0—
    Vanutide cridificarPhase 2PfizerProtein or peptideVaccine antigenAmyloid-beta A4 protein vaccine antigen0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 16 in all, from ClinicalTrials.gov.
    A Postmarketing Study of LEQEMBI in Participants With Alzheimer's DiseaseLecanemab—Not yet recruitingEisai Inc.2026-10-08
    A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's DiseaseDonanemabPhase 4Not yet recruitingEli Lilly and Company2026-09-24
    A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's DiseaseLecanemab—RecruitingEisai Inc.2026-09-16
    Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseaseDonanemab, LecanemabPhase 2Not yet recruitingWake Forest University Health Sciences2026-08-10
    Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's BiomarkersLecanemabPhase 4RecruitingThe Fourth Affiliated Hospital of Zhejiang University School of Medicine2026-07-07
    A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).DonanemabPhase 3RecruitingEli Lilly and Company2026-05-22
    Evaluating the Efficacy and Safety of Lecanemab in Alzheimer's Disease Through Multi-omics ApproachsLecanemabPhase 4RecruitingFirst Affiliated Hospital of Wenzhou Medical University2026-05-22
    A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)DonanemabPhase 2RecruitingEli Lilly and Company2026-05-15
    Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's DiseaseDonanemabPhase 3RecruitingEli Lilly and Company2026-05-06
    Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD PathologyLecanemabNot applicableNot yet recruitingYonsei University2026-04-22
    Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World PracticeLecanemab—Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2026-04-01
    Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica ResonanceDonanemab, LecanemabNot applicableNot yet recruitingIRCCS San Raffaele2026-03-06
    Alzheimer's Tau Platform: Regimen A - AADvac1DonanemabPhase 2Enrolling by invitationPaul S. Aisen2025-09-11
    A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's DiseaseDonanemabPhase 2 / Phase 3RecruitingBanner Health2025-05-30
    Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) TherapyAducanumabEarly phase 1Active, not recruitingAli Rezai2022-07-21
    Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001Gantenerumab, SolanezumabPhase 2 / Phase 3Active, not recruitingWashington University School of Medicine2013-01-03

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Alzheimer disease
    0.81
    Alzheimer disease type 1
    0.79
    Cerebral amyloid angiopathy, APP-related
    0.75
    Hereditary cerebral hemorrhage with amyloidosis
    0.63
    ABeta amyloidosis, dutch type
    0.50
    ABeta amyloidosis, Italian type
    0.50
    ABeta amyloidosis, Iowa type
    0.50
    ABeta amyloidosis, Arctic type
    0.50
    ABetaA21G amyloidosis
    0.50
    ABetaL34V amyloidosis
    0.47

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2487, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P05067, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.